Early and accurate detection is critical for preventing the spread of COVID-19 and providing appropriate care for patients. Nasopharyngeal (NP) swabs, which require inserting a long shaft into the ...
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, a privately held biotech company, today announced its test validation trial for CyPath® Lung resulted in specificity of 88% and sensitivity of ...
SAN ANTONIO, February 25, 2026--bioAffinity Technologies announced validation study with BAMC to assess deep suction sputum samples for lung cancer detection with CyPath Lung.
In a meta-analysis, researchers found that sputum was more accurate than nasopharyngeal or oropharyngeal swabs. The study also shows early testing increased rates of COVID-19 diagnosis. Early and ...
bioAffinity Technologies Publishes Sputum Processing and Innovative High-Throughput Analysis Methods
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced publication in the peer-reviewed Journal of Visualized ...
Current TB tests rely on sputum, mucus collected from the lungs and lower respiratory system. While rich in TB bacteria required for testing, collecting sputum is difficult, making it inefficient for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results